Cargando…

Molecular Basis for Dysregulated Activation of NKX2‐5 in the Vascular Remodeling of Systemic Sclerosis

OBJECTIVE: NKX2‐5 is a homeobox transcription factor that is required for the formation of the heart and vessels during development, with significant postnatal down‐regulation and reactivation in disease states, characterized by vascular remodeling. The purpose of this study was to investigate mecha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dritsoula, Athina, Papaioannou, Ioannis, Guerra, Sandra G., Fonseca, Carmen, Martin, Javier, Herrick, Ariane L., Abraham, David J., Denton, Christopher P., Ponticos, Markella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001790/ https://www.ncbi.nlm.nih.gov/pubmed/29342503 http://dx.doi.org/10.1002/art.40419

Ejemplares similares

Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis
por: Ponticos, Markella, et al.
Publicado: (2015)

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo‐Controlled, Phase II Study
por: Denton, Christopher P., et al.
Publicado: (2017)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
por: Hughes, M., et al.
Publicado: (2016)

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis–Related Raynaud's Phenomenon
por: Wilkinson, Jack D., et al.
Publicado: (2018)

Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study
por: Cutolo, Maurizio, et al.
Publicado: (2016)

Nuclear Receptor Subfamily 4A Signaling as a Key Disease Pathway of CD1c+ Dendritic Cell Dysregulation in Systemic Sclerosis
por: Servaas, Nila H., et al.
Publicado: (2022)

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
por: Clark, Kristina Elizabeth Neergaard, et al.
Publicado: (2023)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis
por: Carvalheiro, Tiago, et al.
Publicado: (2019)

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis
por: Martin, Mickaël, et al.
Publicado: (2019)

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis
por: Ariani, Alarico, et al.
Publicado: (2019)

A stretchable hardness sensor for the assessment of skin disease in systemic sclerosis
por: Wang, Xiuyuan, et al.
Publicado: (2023)

Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers
por: Dumitru, Raluca B, et al.
Publicado: (2021)

Work Productivity and Economic Burden of Systemic Sclerosis in a Multiethnic Asian Population
por: Xiang, Ling, et al.
Publicado: (2022)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies
por: Liem, Sophie I E, et al.
Publicado: (2023)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Risk of kidney failure in patients with systemic sclerosis: a nationwide population-based study
por: Kwon, Oh Chan, et al.
Publicado: (2023)

Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes
por: Gegenava, Tea, et al.
Publicado: (2023)

New risk model is able to identify patients with a low risk of progression in systemic sclerosis
por: van Leeuwen, Nina Marijn, et al.
Publicado: (2021)

Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study
por: Kida, Takashi, et al.
Publicado: (2022)

Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients
por: Beretta, Lorenzo, et al.
Publicado: (2020)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Spontaneous Pulmonary Hypertension Associated With Systemic Sclerosis in P‐Selectin Glycoprotein Ligand 1–Deficient Mice
por: González‐Tajuelo, Rafael, et al.
Publicado: (2020)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Ultrasound quantitative assessment of ventral finger microvasculopathy in systemic sclerosis with Raynaud’s phenomena: a comparative study
por: Nam, Kibo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hgr9hlik01rraf8to345upjg1r